Home LiteratureArticle Details
PMID: 23076159 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.

Nature reviews. Cancer ·Vol. 12 ·No. 11 ·2012-11-00 ·Pages 753-66

Verstraete K, Savvides SN

Abstract

Intracellular signalling cascades initiated by class III receptor tyrosine kinases (RTK-IIIs) and their cytokine ligands contribute to haematopoiesis and mesenchymal tissue development. They are also implicated in a wide range of inflammatory disorders and cancers. Recent snapshots of RTK-III ectodomains in complex with cognate cytokines have revealed timely insights into the structural determinants of RTK-III activation, evolution and pathology. Importantly, candidate 'driver' and 'passenger' mutations that have been identified in RTK-IIIs can now be collectively mapped for the first time to structural scaffolds of the corresponding RTK-III ectodomains. Such insights will generate a renewed interest in dissecting the mechanistic effects of such mutations and their therapeutic relevance.

MeSH Terms
Cell Transformation, Neoplastic Cytokines/metabolism Hematopoiesis/physiology Humans Ligands Mutation Receptor Protein-Tyrosine Kinases/genetics,metabolism,physiology Signal Transduction
Chemicals
Cytokines Ligands Receptor Protein-Tyrosine Kinases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Verstraete Kenneth
Unit for Structural Biology, Laboratory for Protein Biochemistry and Biomolecular Engineering, Ghent University, K.L. Ledeganckstraat 35, 9000 Ghent, Belgium. [email protected]
Savvides Savvas N
References (180)
180 references, click to expand
  1. Many of the immunoglobulin superfamily domains in cell adhesion molecules and surface receptors belong to a new structural set which is close to that containing variable domains.
    J Mol Biol. 1994 May 13;238(4):528-39 PMID: 8176743
  2. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization.
    Blood. 2012 Feb 16;119(7):1781-8 PMID: 22207738
  3. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling.
    Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1906-11 PMID: 20080685
  4. FMS mutations in myelodysplastic, leukemic, and normal subjects.
    Proc Natl Acad Sci U S A. 1990 Feb;87(4):1377-80 PMID: 2406720
  5. Overview of the CCP4 suite and current developments.
    Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42 PMID: 21460441
  6. Targeted therapy in GIST: in silico modeling for prediction of resistance.
    Nat Rev Clin Oncol. 2011 Mar;8(3):161-70 PMID: 21364689
  7. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
    Clin Cancer Res. 2008 Jul 15;14(14):4437-45 PMID: 18628457
  8. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction.
    Cell. 1995 Jan 13;80(1):103-13 PMID: 7529140
  9. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities.
    Blood. 1998 Feb 15;91(4):1101-34 PMID: 9454740
  10. Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases.
    EMBO J. 2007 Feb 7;26(3):891-901 PMID: 17255936
  11. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival.
    J Immunol. 2008 Jun 1;180(11):7358-67 PMID: 18490735
  12. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development.
    Hepatol Res. 2010 Nov;40(11):1128-41 PMID: 20880061
  13. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
    Biochem Pharmacol. 1999 Jan 1;57(1):57-64 PMID: 9920285
  14. The role of FLT3 in haematopoietic malignancies.
    Nat Rev Cancer. 2003 Sep;3(9):650-65 PMID: 12951584
  15. Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.
    Leukemia. 2005 Aug;19(8):1432-8 PMID: 15931264
  16. Protein tyrosine kinase structure and function.
    Annu Rev Biochem. 2000;69:373-98 PMID: 10966463
  17. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases.
    Blood. 2010 Oct 7;116(14):2429-37 PMID: 20581310
  18. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease.
    Curr Top Med Chem. 2009;9(7):599-610 PMID: 19689368
  19. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.
    J Biochem. 2010 Apr;147(4):601-9 PMID: 20147452
  20. Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization.
    Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7681-6 PMID: 18505839
  21. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.
    Cancer Res. 2006 Apr 15;66(8):4349-56 PMID: 16618760
  22. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
    Blood. 2004 Jan 1;103(1):267-74 PMID: 12969963
  23. Hydrophobic matching controls the tilt and stability of the dimeric platelet-derived growth factor receptor (PDGFR) β transmembrane segment.
    J Biol Chem. 2012 Jul 27;287(31):26178-86 PMID: 22619173
  24. Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression.
    Cancer Res. 2007 Mar 1;67(5):1918-26 PMID: 17332318
  25. PDGF receptors as targets in tumor treatment.
    Adv Cancer Res. 2007;97:247-74 PMID: 17419949
  26. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.
    Nat Biotechnol. 2000 Oct;18(10):1065-70 PMID: 11017044
  27. Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex.
    Structure. 2011 Jan 12;19(1):45-55 PMID: 21220115
  28. Role of dimerization and modification of the CSF-1 receptor in its activation and internalization during the CSF-1 response.
    EMBO J. 1991 Feb;10(2):277-88 PMID: 1825054
  29. The discovery of receptor tyrosine kinases: targets for cancer therapy.
    Nat Rev Cancer. 2004 May;4(5):361-70 PMID: 15122207
  30. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Leuk Res. 2006 Mar;30(3):296-302 PMID: 16112192
  31. Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma.
    J Biol Chem. 1993 May 5;268(13):9621-8 PMID: 8486649
  32. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
    Biochem Biophys Res Commun. 2005 Nov 11;337(1):1-13 PMID: 16129412
  33. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases.
    Mol Cells. 2010 May;29(5):443-8 PMID: 20432069
  34. The origin and evolution of mutations in acute myeloid leukemia.
    Cell. 2012 Jul 20;150(2):264-78 PMID: 22817890
  35. Ligand-induced homo- and hetero-dimerization of platelet-derived growth factor alpha- and beta-receptors in intact cells.
    Growth Factors. 1992;6(1):1-14 PMID: 1317195
  36. The stem cell factor receptor/c-Kit as a drug target in cancer.
    Curr Cancer Drug Targets. 2006 Feb;6(1):65-75 PMID: 16475976
  37. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation.
    Cell Death Differ. 2010 Dec;17(12):1917-27 PMID: 20489731
  38. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling.
    Blood. 2012 Feb 23;119(8):1810-20 PMID: 22186992
  39. Cell signaling by receptor tyrosine kinases.
    Cell. 2010 Jun 25;141(7):1117-34 PMID: 20602996
  40. A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation.
    J Biol Chem. 2004 Oct 15;279(42):43448-61 PMID: 15297464
  41. Structure of the active core of human stem cell factor and analysis of binding to its receptor kit.
    EMBO J. 2000 Jul 3;19(13):3192-203 PMID: 10880433
  42. Identification and characterization of a functional murine FLT3 isoform produced by exon skipping.
    J Biol Chem. 1995 Feb 17;270(7):3165-71 PMID: 7531700
  43. Kit receptor dimerization is driven by bivalent binding of stem cell factor.
    J Biol Chem. 1997 Mar 7;272(10):6311-7 PMID: 9045650
  44. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
    Cancer. 2010 Feb 15;116(4 Suppl):1013-7 PMID: 20127944
  45. Increasing bioactivity of Flt3 ligand by fusing two identical soluble domains.
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002 Nov;34(6):697-702 PMID: 12417909
  46. Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. Identification of PDGF binding site and neutralizing monoclonal antibodies.
    J Biol Chem. 1997 Dec 26;272(52):33037-44 PMID: 9407086
  47. Cancer statistics, 2012.
    CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 PMID: 22237781
  48. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
    Blood. 2011 Mar 24;117(12):3286-93 PMID: 21263155
  49. A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.
    Biochem J. 1999 Feb 15;338 ( Pt 1):131-8 PMID: 9931308
  50. Rethinking bioactivity of FLT3 inhibitors.
    Blood. 2011 Mar 24;117(12):3247-8 PMID: 21436074
  51. Allosteric competitive inactivation of hematopoietic CSF-1 signaling by the viral decoy receptor BARF1.
    Nat Struct Mol Biol. 2012 Sep;19(9):938-47 PMID: 22902366
  52. Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
    Nat Rev Cancer. 2004 Sep;4(9):718-27 PMID: 15343278
  53. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.
    J Invest Dermatol. 2010 Mar;130(3):804-15 PMID: 19865100
  54. Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor.
    J Biol Chem. 1993 Feb 15;268(5):3625-31 PMID: 7679113
  55. The biology of stem cell factor and its receptor C-kit.
    Int J Biochem Cell Biol. 1999 Oct;31(10):1037-51 PMID: 10582338
  56. Structure elucidation of dimeric transmembrane domains of bitopic proteins.
    Cell Adh Migr. 2010 Apr-Jun;4(2):284-98 PMID: 20421711
  57. Further activation of FLT3 mutants by FLT3 ligand.
    Oncogene. 2011 Sep 22;30(38):4004-14 PMID: 21516120
  58. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain.
    J Mol Biol. 2007 Mar 30;367(3):839-47 PMID: 17292918
  59. D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias.
    Genes Chromosomes Cancer. 2006 Apr;45(4):332-7 PMID: 16320249
  60. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Cell Signal. 2007 Dec;19(12):2572-81 PMID: 17855052
  61. Transforming activities of human CSF-1 receptors with different point mutations at codon 301 in their extracellular domains.
    Oncogene. 1990 Jan;5(1):25-30 PMID: 2157180
  62. Phosphorylation in the activation loop as the finishing touch in c-Kit activation.
    J Biochem. 2012 May;151(5):457-9 PMID: 22437942
  63. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase.
    EMBO J. 1991 Sep;10(9):2451-9 PMID: 1714377
  64. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.
    EMBO J. 1988 Apr;7(4):1003-11 PMID: 2456920
  65. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases.
    EMBO J. 1993 Jun;12(6):2257-64 PMID: 7685273
  66. CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas.
    Mod Pathol. 2009 Jun;22(6):744-52 PMID: 19377443
  67. Colony-stimulating factor-1 in immunity and inflammation.
    Curr Opin Immunol. 2006 Feb;18(1):39-48 PMID: 16337366
  68. Anti-human FLT3 monoclonal antibody that inhibits proliferation of monocytic leukemia cell line SHI-1.
    Hybridoma (Larchmt). 2011 Feb;30(1):61-7 PMID: 21466287
  69. Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth.
    Cancer Res. 2012 Jan 1;72(1):187-200 PMID: 22052465
  70. Passenger deletions generate therapeutic vulnerabilities in cancer.
    Nature. 2012 Aug 16;488(7411):337-42 PMID: 22895339
  71. Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.
    Neoplasia. 2009 Jun;11(6):594-604 PMID: 19484148
  72. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update.
    Exp Biol Med (Maywood). 2004 Jan;229(1):1-11 PMID: 14709771
  73. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells.
    J Leukoc Biol. 2010 Sep;88(3):495-505 PMID: 20504948
  74. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.
    Mol Cell. 2004 Jan 30;13(2):169-78 PMID: 14759363
  75. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
    Leukemia. 1998 Sep;12(9):1333-7 PMID: 9737679
  76. Surface binding inhibitors of the SCF-KIT protein-protein interaction.
    Chembiochem. 2009 Aug 17;10(12):1955-8 PMID: 19637142
  77. An antibody reactive with domain 4 of the platelet-derived growth factor beta receptor allows BB binding while inhibiting proliferation by impairing receptor dimerization.
    J Biol Chem. 1997 Jul 11;272(28):17400-4 PMID: 9211881
  78. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
    Cancer Cell. 2007 Dec;12(6):501-13 PMID: 18068628
  79. Inducible production of recombinant human Flt3 ectodomain variants in mammalian cells and preliminary crystallographic analysis of Flt3 ligand-receptor complexes.
    Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Mar 1;67(Pt 3):325-31 PMID: 21393836
  80. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.
    Biochemistry. 2006 May 23;45(20):6241-51 PMID: 16700535
  81. The PDGF family: four gene products form five dimeric isoforms.
    Cytokine Growth Factor Rev. 2004 Aug;15(4):197-204 PMID: 15207811
  82. Extracellular complexes of the hematopoietic human and mouse CSF-1 receptor are driven by common assembly principles.
    Structure. 2011 Dec 7;19(12):1762-72 PMID: 22153499
  83. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family.
    Oncogene. 1991 Sep;6(9):1641-50 PMID: 1656368
  84. Structure of a c-kit product complex reveals the basis for kinase transactivation.
    J Biol Chem. 2003 Aug 22;278(34):31461-4 PMID: 12824176
  85. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.
    Blood. 2010 Aug 19;116(7):1114-23 PMID: 20484085
  86. Specific inhibition of a pathogenic receptor tyrosine kinase by its transmembrane domain.
    Biochim Biophys Acta. 2011 Jan;1808(1):253-9 PMID: 20713021
  87. Structure of a VEGF-VEGF receptor complex determined by electron microscopy.
    Nat Struct Mol Biol. 2007 Mar;14(3):249-50 PMID: 17293873
  88. Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex.
    Blood. 2011 Jul 7;118(1):60-8 PMID: 21389326
  89. c-FMS inhibitors: a patent review.
    Expert Opin Ther Pat. 2011 Feb;21(2):147-65 PMID: 21204725
  90. KIT mutations in GIST.
    Curr Opin Genet Dev. 2007 Feb;17(1):3-7 PMID: 17208434
  91. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.
    Leukemia. 2012 Jun;26(6):1228-37 PMID: 22289926
  92. Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers.
    FASEB J. 2010 Jan;24(1):32-8 PMID: 19726758
  93. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.
    Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50 PMID: 20952405
  94. Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.
    Cancer Sci. 2012 Feb;103(2):350-9 PMID: 22049994
  95. Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen.
    J Biol Chem. 1998 Jul 10;273(28):17626-33 PMID: 9651358
  96. Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.
    Sarcoma. 2010;2010:174528 PMID: 20981142
  97. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.
    Mol Cell Biol. 2003 May;23(9):3067-78 PMID: 12697809
  98. Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R.
    Structure. 2012 Apr 4;20(4):676-87 PMID: 22483114
  99. Structure of macrophage colony stimulating factor bound to FMS: diverse signaling assemblies of class III receptor tyrosine kinases.
    Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18267-72 PMID: 19017797
  100. Crystal structure of human platelet-derived growth factor BB.
    EMBO J. 1992 Nov;11(11):3921-6 PMID: 1396586
  101. Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor.
    J Biol Chem. 1992 Aug 5;267(22):15970-7 PMID: 1379243
  102. Targeting cancer with small molecule kinase inhibitors.
    Nat Rev Cancer. 2009 Jan;9(1):28-39 PMID: 19104514
  103. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
    Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2425-30 PMID: 20145116
  104. Receptor tyrosine kinases: from biology to pathology.
    J Recept Signal Transduct Res. 2011 Dec;31(6):387-94 PMID: 22040163
  105. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Blood. 2005 Jul 15;106(2):721-4 PMID: 15790786
  106. Genomic structure of human FLT3: implications for mutational analysis.
    Br J Haematol. 2001 Jun;113(4):1076-7 PMID: 11442505
  107. PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs.
    J Orthop Res. 2011 Dec;29(12):1795-803 PMID: 21618276
  108. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets.
    Nat Rev Cancer. 2012 Aug;12(8):572-8 PMID: 22739505
  109. Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization.
    J Biol Chem. 1997 May 9;272(19):12676-82 PMID: 9139724
  110. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Blood. 2004 Apr 15;103(8):3222-5 PMID: 15070706
  111. Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics.
    Cell Adh Migr. 2010 Apr-Jun;4(2):249-54 PMID: 20168077
  112. Juxtamembrane autoinhibition in receptor tyrosine kinases.
    Nat Rev Mol Cell Biol. 2004 Jun;5(6):464-71 PMID: 15173825
  113. FLT3/ITD AML and the law of unintended consequences.
    Blood. 2011 Jun 30;117(26):6987-90 PMID: 21586749
  114. Monoclonal antibodies: versatile platforms for cancer immunotherapy.
    Nat Rev Immunol. 2010 May;10(5):317-27 PMID: 20414205
  115. Protein-protein interaction inhibitors get into the groove.
    Nat Rev Drug Discov. 2012 Mar 01;11(3):173-5 PMID: 22378255
  116. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.
    Cancer. 2010 Feb 15;116(4 Suppl):1018-26 PMID: 20127943
  117. Strong oligomerization behavior of PDGFbeta receptor transmembrane domain and its regulation by the juxtamembrane regions.
    Biochim Biophys Acta. 2010 Mar;1798(3):605-15 PMID: 20036637
  118. PDGF receptors as cancer drug targets.
    Cancer Cell. 2003 May;3(5):439-43 PMID: 12781361
  119. Oncogenic derivatives of platelet-derived growth factor receptors.
    Cell Mol Life Sci. 2004 Dec;61(23):2912-23 PMID: 15583853
  120. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis.
    Am J Blood Res. 2012;2(1):44-56 PMID: 22432087
  121. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
    Oncogene. 2002 Apr 11;21(16):2555-63 PMID: 11971190
  122. Soluble kit receptor in human serum.
    Blood. 1995 Jan 1;85(1):66-73 PMID: 7528574
  123. Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation.
    Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7732-7 PMID: 10884405
  124. The GIST paradigm: lessons for other kinase-driven cancers.
    J Pathol. 2011 Jan;223(2):251-61 PMID: 21125679
  125. Regulation of the catalytic activity of the EGF receptor.
    Curr Opin Struct Biol. 2011 Dec;21(6):777-84 PMID: 21868214
  126. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.
    Biochem Biophys Res Commun. 2011 Jul 1;410(2):224-8 PMID: 21640708
  127. Development of dendritic-cell lineages.
    Immunity. 2007 Jun;26(6):741-50 PMID: 17582346
  128. Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells.
    Proc Natl Acad Sci U S A. 2010 May 25;107(21):9759-64 PMID: 20457904
  129. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):88-99 PMID: 18537751
  130. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia.
    Nat Immunol. 2012 Jun 24;13(8):753-60 PMID: 22729249
  131. In vivo analysis of dendritic cell development and homeostasis.
    Science. 2009 Apr 17;324(5925):392-7 PMID: 19286519
  132. The single transmembrane domains of human receptor tyrosine kinases encode self-interactions.
    Sci Signal. 2009 Sep 22;2(89):ra56 PMID: 19797273
  133. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).
    Oncol Rep. 2009 Jun;21(6):1359-66 PMID: 19424610
  134. Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor.
    Nat Struct Mol Biol. 2011 Aug 07;18(9):984-9 PMID: 21822280
  135. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
    J Clin Oncol. 2005 Feb 10;23(5):973-81 PMID: 15466784
  136. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor.
    Proc Natl Acad Sci U S A. 1989 Jul;86(13):4917-21 PMID: 2544881
  137. The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1.
    Biochim Biophys Acta. 2012 Jul;1824(7):938-45 PMID: 22579672
  138. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.
    Mol Biol Cell. 2000 Oct;11(10):3589-99 PMID: 11029057
  139. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.
    Blood. 2005 Dec 1;106(12):3958-61 PMID: 16081693
  140. Gastrointestinal stromal tumours: origin and molecular oncology.
    Nat Rev Cancer. 2011 Nov 17;11(12):865-78 PMID: 22089421
  141. Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots.
    Nat Struct Biol. 2000 Jun;7(6):486-91 PMID: 10881197
  142. FMS Kinase Inhibitors: Current Status and Future Prospects.
    Med Res Rev. 2013 May;33(3):599-636 PMID: 22434539
  143. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.
    Eur J Pharmacol. 2006 Mar 8;533(1-3):327-40 PMID: 16483568
  144. Colony-stimulating factors in inflammation and autoimmunity.
    Nat Rev Immunol. 2008 Jul;8(7):533-44 PMID: 18551128
  145. High-throughput selection of transmembrane sequences that enhance receptor tyrosine kinase activation.
    J Mol Biol. 2011 Sep 9;412(1):43-54 PMID: 21767549
  146. Structural and functional alterations of FLT3 in acute myeloid leukemia.
    Clin Cancer Res. 2009 Jul 1;15(13):4263-9 PMID: 19549778
  147. FLT3 as a therapeutic target in AML: still challenging after all these years.
    Blood. 2010 Dec 9;116(24):5089-102 PMID: 20705759
  148. Monoclonal antibody-based therapeutics for leukemia.
    Expert Opin Biol Ther. 2007 Mar;7(3):319-30 PMID: 17309324
  149. c-fms point mutations in acute myeloid leukemia: fact or fiction?
    Leukemia. 1993 Jul;7(7):978-85 PMID: 8321048
  150. Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events.
    J Biol Chem. 1998 Jul 3;273(27):17050-5 PMID: 9642269
  151. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9026-30 PMID: 1717995
  152. Imatinib mesylate.
    Recent Results Cancer Res. 2010;184:3-20 PMID: 20072827
  153. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
    Blood. 2004 Aug 15;104(4):1137-44 PMID: 15105287
  154. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.
    Cell. 2007 Jul 27;130(2):323-34 PMID: 17662946
  155. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors.
    J Biol Chem. 2007 Feb 9;282(6):4094-101 PMID: 17132624
  156. The protein tyrosine kinase family of the human genome.
    Oncogene. 2000 Nov 20;19(49):5548-57 PMID: 11114734
  157. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential.
    Cell. 1988 Dec 23;55(6):979-88 PMID: 2974321
  158. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome.
    Science. 2008 May 9;320(5877):807-11 PMID: 18467591
  159. The majority of stem cell factor exists as monomer under physiological conditions. Implications for dimerization mediating biological activity.
    J Biol Chem. 1997 Mar 7;272(10):6406-15 PMID: 9045664
  160. The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues.
    Protein Sci. 2009 Feb;18(2):450-9 PMID: 19165726
  161. Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains.
    Mol Biol Evol. 2006 Jun;23(6):1232-41 PMID: 16551648
  162. Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis.
    Blood. 1998 Feb 1;91(3):879-89 PMID: 9446648
  163. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
    Cancer. 2011 Aug 1;117(15):3293-304 PMID: 21319142
  164. Development trends for human monoclonal antibody therapeutics.
    Nat Rev Drug Discov. 2010 Oct;9(10):767-74 PMID: 20811384
  165. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues.
    Nat Immunol. 2008 Jun;9(6):676-83 PMID: 18469816
  166. Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent.
    Cancer Biol Ther. 2002 Sep-Oct;1(5):486-9 PMID: 12496473
  167. Receptor tyrosine kinase transmembrane domain interactions: potential target for "interceptor" therapy.
    Sci Signal. 2010 Sep 07;3(138):jc6 PMID: 20823401
  168. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow.
    Nat Immunol. 2007 Nov;8(11):1207-16 PMID: 17922016
  169. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors.
    Nature. 1986 Sep 18-24;323(6085):226-32 PMID: 3020426
  170. Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor.
    Science. 1992 Nov 20;258(5086):1358-62 PMID: 1455231
  171. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus.
    Nature. 1986 Mar 20-26;320(6059):277-80 PMID: 2421165
  172. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
    Leukemia. 2011 Sep;25(9):1423-32 PMID: 21606963
  173. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics.
    Drug Resist Updat. 2005 Feb-Apr;8(1-2):75-83 PMID: 15939344
  174. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex.
    Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11307-12 PMID: 20534510
  175. The immunoglobulin superfamily: an insight on its tissular, species, and functional diversity.
    J Mol Evol. 1998 Apr;46(4):389-400 PMID: 9541533
  176. Spatial regulation of receptor tyrosine kinases in development and cancer.
    Nat Rev Cancer. 2012 May 24;12(6):387-400 PMID: 22622641
  177. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
    Expert Opin Emerg Drugs. 2011 Sep;16(3):407-23 PMID: 21417961
  178. Role of platelet-derived growth factors in physiology and medicine.
    Genes Dev. 2008 May 15;22(10):1276-312 PMID: 18483217
  179. Hematopoietic cytokines.
    Blood. 2008 Jan 15;111(2):485-91 PMID: 18182579
  180. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
    Nature. 2012 Jan 11;481(7380):157-63 PMID: 22237106
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc3371
Email
[email protected]
Published
2012-11-00
Epub
2012-00-18
Pages
753-66
Language
English
Region
England
NLM ID
101124168
Subset
IM
External Links
PubMed source DOI: 10.1038/nrc3371 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2